TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12942401

Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg twice per day
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Azithromycin, 500 mg once per day
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study: 10789592

Group type: EXPERIMENTAL
Intervention: IFN-alpha-2a, 6 MIU s.c. TIW for 4 weeks, followed by 3 MIU s.c. TIW, and 13-cis-retinoic acid 1 mg/kg/day p.o. BID daily
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Trophosphamide 100-150 mg/day p.o. BID
Number of subjects: 85

Group type: COMPARATOR
Intervention: No maintenance treatment (Control group)
Number of subjects: 85
Study: 8863199

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 17
Study: 8262820

Group type: EXPERIMENTAL
Intervention: BFM chemotherapy with 1800 cGy cranial irradiation
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: LSA2L2 chemotherapy with 1800 cGy cranial irradiation and 1500 cGy to nonabdominal bulk disease
Number of subjects: 308

Group type: COMPARATOR
Intervention: Reg B without cranial irradiation
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Chest radiation for Regimen B and C patients with large mediastinal masses
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Cranial fields encompassing the entire meningeal surface
Number of subjects: 308
Study: 3897345

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 29793484

Group type: EXPERIMENTAL
Intervention: COPD patients (TBR: 1.90 ± 0.38, aPWV: 9.9 ± 2.6 m/s)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: α1ATD-COPD patients (TBR: 1.94 ± 0.43, aPWV: 9.5 ± 1.8 m/s)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Smokers (TBR: 1.74 ± 0.30, aPWV: 7.8 ± 1.8 m/s)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Never-smokers (TBR: 1.71 ± 0.34, aPWV: 7.9 ± 1.7 m/s)
Number of subjects: 121
Study: 27552838

Group type: EXPERIMENTAL
Intervention: Ultrasonic K‐file
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Irrisafe file
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Smooth wire
Number of subjects: 72

Group type: COMPARATOR
Intervention: No activation (group D)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Activation time
Number of subjects: 72
Study: 24568874

Group type: EXPERIMENTAL
Intervention: Extended sensorimotor experience with the objects
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brief sensorimotor experience with the objects
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reading written information about the objects' weights
Number of subjects: 60
Study: 22222856

Group type: EXPERIMENTAL
Intervention: 0.5 mg BHT-3009
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 1.5 mg BHT-3009
Number of subjects: 155
Study: 20212267

Group type: EXPERIMENTAL
Intervention: Weight loss via a hypocaloric diet
Number of subjects: 36
Study: 18567749

Group type: EXPERIMENTAL
Intervention: 80 mg isoflavones (ISO)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 22
Study: 16020596

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 49

Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: II genotype
Number of subjects: 49
Study: 14643954

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with a fraction dose of 1.8 Gy to a median total dose of 54 Gy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 33
Study: 10471608

Group type: EXPERIMENTAL
Intervention: p55‐IgG, 0.083 mg/kg
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 8760850

Group type: EXPERIMENTAL
Intervention: Visible light-cured fluoride-releasing material
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chemically cured nonfluoride resin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall evaluation of white spots
Number of subjects: 50
Study: 1657199

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (0.15 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 6401510

Group type: EXPERIMENTAL
Intervention: Long-term maintenance treatment with cimetidine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Proximal gastric vagotomy
Number of subjects: 44
Study: 30887953

Group type: EXPERIMENTAL
Intervention: Mixed work pattern
Number of subjects: 1045

Group type: COMPARATOR
Intervention: 12/24 h work pattern
Number of subjects: 1045

Group type: COMPARATOR
Intervention: 2 day/night shifts
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Single day shift
Number of subjects: 1045
Study: 27880011

Group type: EXPERIMENTAL
Intervention: Ceramic Repair (37% phosphoric acid + Monobond‐S + Heliobond + Tetric N Ceram)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil Repair (40% phosphoric acid + mixture of Clearfil Porcelain Bond Activator and Clearfil SE Bond Primer + Clearfil SE Bond + Filtek Z250)
Number of subjects: 0
Study: 26883504

Group type: EXPERIMENTAL
Intervention: Self-management intervention (home-based exercise program 3 times a week + physical therapy once every 2 weeks for 14 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care physical therapy (physical therapy twice a week + home-based exercise program once a week for 14 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care physical therapy
Number of subjects: 30
Study: 25028463

Group type: EXPERIMENTAL
Intervention: Moxifloxacin regimen (M, H, R, Z, E)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Control regimen (RHZE thrice weekly)
Number of subjects: 780
Study: 22591731

Group type: EXPERIMENTAL
Intervention: Cluster analysis of eating disorder symptoms and personality characteristics
Number of subjects: 70
Study: 19781902

Group type: EXPERIMENTAL
Intervention: OffPCABG
Number of subjects: 81

Group type: COMPARATOR
Intervention: OnPCABG
Number of subjects: 81
Study: 17513285

Group type: EXPERIMENTAL
Intervention: Telemonitored clinical care
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 16148461

Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis
Number of subjects: 626

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 626
Study: 11827839

Group type: EXPERIMENTAL
Intervention: Comprehensive form A (50 questions)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Shorter form B (37 questions)
Number of subjects: 194
Study: 10102058

Group type: EXPERIMENTAL
Intervention: GH 1.0 IU/kg/week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GH 1.5 IU/kg/week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GH 0.5 IU/kg/week (first year), 0.75 IU/kg/week (second year), 1.0 IU/kg/week (third year), 0.5 IU/kg/week (fourth year)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group GH 0.5 IU/kg/week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both protocols from the two studies
Number of subjects: 30
Study: 7539544

Group type: EXPERIMENTAL
Intervention: 1 mg glucagon
Number of subjects: 74

Group type: COMPARATOR
Intervention: 40 mg hyoscine N-butyl bromide
Number of subjects: 74
Study: 1970460

Group type: EXPERIMENTAL
Intervention: Nifedipine 1 mg i.v. with atracurium
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nifedipine 1 mg i.v. during continuous relaxation with atracurium or vecuronium
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Nifedipine 1 mg i.v. at the end of anesthesia
Number of subjects: 44
Study: 7019558

Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution (0.1% - 0.5%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pilocarpine eye drops (1% - 4%)
Number of subjects: 50
Study: 31677583

Group type: EXPERIMENTAL
Intervention: Self-management for people with epilepsy (SMART) program
Number of subjects: 120
Study: 28651793

Group type: EXPERIMENTAL
Intervention: IM+oral therapy (intramuscular + daily oral)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Daily oral-only therapy
Number of subjects: 231
Study: 25805436

Group type: EXPERIMENTAL
Intervention: WARP technique at 1.5T and 3T MRI
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard sequences at 1.5T and 3T MRI
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: WARP technique at 3T MRI
Number of subjects: 19
Study: 24115797

Group type: EXPERIMENTAL
Intervention: Home-care package
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community-care strategy
Number of subjects: 0
Study: 21866096

Group type: EXPERIMENTAL
Intervention: GSK1018921 (0.5 to 280 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GSK1018921
Number of subjects: 25
Study: 19265025

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin daily for 6 weeks, then 20 mg from weeks 6 to 12
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin daily for 6 weeks, then 20 mg from weeks 6 to 12
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo for 6 weeks, then 20 mg rosuvastatin from weeks 6 to 12
Number of subjects: 318
Study: 18058850

Group type: EXPERIMENTAL
Intervention: Multistate model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint longitudinal-survival model
Number of subjects: 0
Study: 14973794

Group type: EXPERIMENTAL
Intervention: Off-pump techniques (OPCAB group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (CPB group)
Number of subjects: 50
Study: 11573665

Group type: EXPERIMENTAL
Intervention: General anaesthesia plus epidural analgesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 30
Study: 9574890

Group type: EXPERIMENTAL
Intervention: High allergen content NRL gloves
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: High allergen content NRL gloves with skin protection cream
Number of subjects: 109

Group type: COMPARATOR
Intervention: Low allergen content NRL gloves
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Low allergen content NRL gloves with skin protection cream
Number of subjects: 109
Study: 8166094

Group type: EXPERIMENTAL
Intervention: Rotary electric toothbrush (Rota‐dent) with standard fluoride toothpaste and 0.05% sodium fluoride rinse
Number of subjects: 90

Group type: COMPARATOR
Intervention: Manual toothbrushing with standard fluoride toothpaste
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Manual toothbrushing with standard fluoride toothpaste and daily use of a 0.05% sodium fluoride rinse
Number of subjects: 90
Study: 3294442

Group type: EXPERIMENTAL
Intervention: Acetohydroxamic acid
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 29630721

Group type: EXPERIMENTAL
Intervention: Yimitasvir phosphate 30 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Yimitasvir phosphate 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Yimitasvir phosphate 200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28025025

Group type: EXPERIMENTAL
Intervention: Finerenone (1.25-20mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 26594626

Group type: EXPERIMENTAL
Intervention: Levodopa and STN-DBS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: STN-DBS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (age-matched healthy participants)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PD patients
Number of subjects: 12
Study: 21919119

Group type: EXPERIMENTAL
Intervention: Emotionally Focused Therapy (EFT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study: 21514589

Group type: EXPERIMENTAL
Intervention: Plant stanol esters (3.0 g/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no added plant stanols)
Number of subjects: 24
Study: 17458395

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study: 14730218

Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM) 400 mg/day orally for 14 days prior to surgery and for 7 days following surgery, in addition to flomoxef
Number of subjects: 26

Group type: COMPARATOR
Intervention: Flomoxef (control group) administered for 4-7 days following surgery
Number of subjects: 26
Study: 11506400

Group type: EXPERIMENTAL
Intervention: Embryonic dopamine cell implantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 40
Study: 9563352

Group type: EXPERIMENTAL
Intervention: Fuji Ortho (self-curing resin-modified glass-ionomer cement)
Number of subjects: 60

Group type: COMPARATOR
Intervention: System 1+ (composite resin)
Number of subjects: 60
Study: 10150185

Group type: EXPERIMENTAL
Intervention: Trimetazidine 1 mg.kg‐1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Trimetazidine 1.5 mg.kg‐1
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 3067546

Group type: EXPERIMENTAL
Intervention: CV 205-502 (0.05 micrograms daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CV 205-502
Number of subjects: 12
Study: 29649795

Group type: EXPERIMENTAL
Intervention: HD combined with hemoperfusion (HD + HP)
Number of subjects: 40
Study: 26698929

Group type: EXPERIMENTAL
Intervention: ETN + MTX
Number of subjects: 222

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Continue ETN
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Discontinue ETN
Number of subjects: 222
Study: 23832397

Group type: EXPERIMENTAL
Intervention: MSC1992371A administered on days 1 and 8 (schedule 1)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: MSC1992371A administered on days 1, 2, and 3 (schedule 2)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: MSC1992371A administered on days 1-3 and 8-10 (schedule 3)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: MSC1992371A
Number of subjects: 92
Study: 23110951

Group type: COMPARATOR
Intervention: Flunixin meglumine (FM)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 6
Study: 20609183

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) at 1.8 g/day for 12 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (5 biopsy-confirmed IgA nephropathy patients)
Number of subjects: 18
Study: 18338758

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 277

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 277
Study: 16383032

Group type: EXPERIMENTAL
Intervention: i.v. infusion of 50 g/L CISS, 2,000 ml per day (Group A)
Number of subjects: 53

Group type: COMPARATOR
Intervention: i.v. infusion of 50 g/L glucose, 2,000 ml per day (Group B)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 53

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 53
Study: 12394711

Group type: EXPERIMENTAL
Intervention: Korean red ginseng (900 mg, 3 times daily)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Korean red ginseng
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 10088031

Group type: EXPERIMENTAL
Intervention: Levocabastine nasal spray (0.2 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7749531

Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation and intraoperative salvage using the Cell Saver
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Postoperative salvage and retransfusion of wound drainage blood using the Solcotrans System
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Intraoperative salvage using the Cell Saver
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation
Number of subjects: 155
Study: 2259928

Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (800 mg per day)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard-dose megestrol acetate (160 mg per day)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard-dose megestrol acetate
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 172
Study: 42529

Group type: EXPERIMENTAL
Intervention: Intranasal LH-RH
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 31486156

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 143749

Group type: EXPERIMENTAL
Intervention: Maternal mortality
Number of subjects: 143749

Group type: EXPERIMENTAL
Intervention: Perinatal death
Number of subjects: 143749

Group type: EXPERIMENTAL
Intervention: Incidence of placental abruption
Number of subjects: 143749

Group type: EXPERIMENTAL
Intervention: Emergency Cesarean section
Number of subjects: 143749
Study: 30723189

Group type: EXPERIMENTAL
Intervention: Overground exoskeleton‐assisted gait training (OEAGT)
Number of subjects: 46
Study: 27672116

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 166

Group type: COMPARATOR
Intervention: Centre-based rehabilitation
Number of subjects: 166
Study: 25800345

Group type: EXPERIMENTAL
Intervention: Diagnostic criteria for immunoglobulin G4-related diseases
Number of subjects: 0
Study: 23672359

Group type: EXPERIMENTAL
Intervention: Intervention group: Verified telephone numbers, obtained best contact times, and informed subjects of planned follow-up calls.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group: Telephone numbers obtained from registration materials without verification, subjects not informed of planned follow-up calls.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study: 20427106

Group type: EXPERIMENTAL
Intervention: Three-dimensional simulation using Surgicase CMF Materialise software
Number of subjects: 17

Group type: COMPARATOR
Intervention: Condylectomy and condylar reconstruction using vertical sliding osteotomy without three-dimensional simulation
Number of subjects: 17
Study: 19265745

Group type: EXPERIMENTAL
Intervention: Diaphragm plus microbicide (Acidform)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Diaphragm plus placebo gel hydroxyethyl cellulose (HEC)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Acidform alone
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: HEC alone
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Gel-diaphragm users
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Gel-only users
Number of subjects: 192
Study: 17479444

Group type: EXPERIMENTAL
Intervention: Combined T3/T4 therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: T4 alone
Number of subjects: 20
Study: 15207442

Group type: EXPERIMENTAL
Intervention: Seropositivity for 3 viruses (herpes simplex type 1, herpes simplex type 2, cytomegalovirus)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Viral burden (0-1, 2, and 3 positive titers)
Number of subjects: 383

Group type: COMPARATOR
Intervention: 2 seropositivities
Number of subjects: 383

Group type: COMPARATOR
Intervention: 3 seropositivities
Number of subjects: 383

Group type: COMPARATOR
Intervention: Baseline MMSE score
Number of subjects: 383
Study: 11742168

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type-A (Botox) injection - 10 units to each side of the puborectalis or 20 units to the posterior aspect of this muscle.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Further injections of Botox (1-5 every 3 months) for those who did not respond to the first injection.
Number of subjects: 25
Study: 9537613

Group type: EXPERIMENTAL
Intervention: Iron glycine (1.4 mg added Fe/serving)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ferrous sulfate (1.4 mg added Fe/serving)
Number of subjects: 9
Study: 8018689

Group type: EXPERIMENTAL
Intervention: 7 weekly sessions on nutrition and behavior modification
Number of subjects: 39

Group type: COMPARATOR
Intervention: Lecture and brief video on diet and cholesterol
Number of subjects: 39
Study: 2574549

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 917713

Group type: EXPERIMENTAL
Intervention: Attending to the stimulus material
Number of subjects: 111

Group type: COMPARATOR
Intervention: Attending to the interval of passing time
Number of subjects: 111

Group type: COMPARATOR
Intervention: Three different interval conditions
Number of subjects: 111
Study: 31591130

Group type: EXPERIMENTAL
Intervention: NTM-1634 at 0.33 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NTM-1634 at 0.66 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: NTM-1634 at 1 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28383362

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26012700

Group type: EXPERIMENTAL
Intervention: Web-based prostate cancer treatment decision aid (DA) offered after diagnosis.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual information and decisional support (Control group).
Number of subjects: 19
Study: 24687643

Group type: EXPERIMENTAL
Intervention: iPad-based briefing (EB)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Classic written briefing
Number of subjects: 101
Study: 22754476

Group type: EXPERIMENTAL
Intervention: Full-body skin examination by a clinician with presumptive diagnosis (abnormal finding, no abnormal finding)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Follow-up care as advised
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Behavioral and cognitive variables
Number of subjects: 312
Study: 18177867

Group type: EXPERIMENTAL
Intervention: 7.5 mg/day letrozole
Number of subjects: 64

Group type: COMPARATOR
Intervention: 150 mg/day clomiphene citrate (CC)
Number of subjects: 64